Abstract
The function of the microbiome in human health and disease has become one of the most important issues in modern medicine. Currently, a growing number of studies are being done to explain the connection between the prevalence of Parkinson’s disease and gut microbial dysbiosis. Both the central nervous system (CNS) and the enteric nervous system (ENS) are affected in a specific way by gut microbial dysbiosis, suggesting that there is a gut-microbiota-brain axis that underlies CNS abnormalities. Neuroinflammation and gut-inflammation-immune responses are suppressed by certain gut microbes, Certain gut microbes exhibit a double-edged sword effect, potentially influencing the development of Parkinson’s disease in both detrimental and protective ways. The immune system, the metabolism of tryptophan, the vagus nerve and the ENS are some of the pathways by which the brain and gut microbiota communicate. These pathways also involve microbial metabolites such as short-chain fatty acids (SCFAs), branched chain amino acids and peptidoglycans. Moreover, oral Porphyromonas gingivalis (P. gingivalis) has been shown in animal models to influence the gut-brain axis, which may indicate the existence of an oral-gut-brain axis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abildgaard A, Elfving B, Hokland M, Wegener G, Lund S (2017) Probiotic treatment reduces depressive-like behaviour in rats independently of diet. Psychoneuroendocrinology 79:40–48. https://doi.org/10.1016/j.psyneuen.2017.02.014
Adams B, Nunes JM, Page MJ, Roberts T, Carr J, Nell TA, Kell DB, Pretorius E (2019) Parkinson’s disease: a systemic inflammatory disease accompanied by bacterial inflammagens. Front Aging Neurosci 11:210. https://doi.org/10.3389/fnagi.2019.00210
Ait-Belgnaoui A, Durand H, Cartier C, Chaumaz G, Eutamene H, Ferrier L, Houdeau E, Fioramonti J, Bueno L, Theodorou V (2012) Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats. Psychoneuroendocrinology 37(11):1885–1895. https://doi.org/10.1016/j.psyneuen.2012.03.024
Akami M, Andongma AA, Zhengzhong C, Nan J, Khaeso K, Jurkevitch E, Niu CY, Yuval B (2019) Intestinal bacteria modulate the foraging behavior of the oriental fruit fly Bactrocera dorsalis (Diptera: Tephritidae). PLoS One 14(1):e0210109. https://doi.org/10.1371/journal.pone.0210109
Amar S, Engelke M (2015) Periodontal innate immune mechanisms relevant to atherosclerosis. Mol Oral Microbiol 30(3):171–185. https://doi.org/10.1111/omi.12087
Arimatsu K, Yamada H, Miyazawa H, Minagawa T, Nakajima M, Ryder MI, Gotoh K, Motooka D, Nakamura S, Iida T, Yamazaki K (2014) Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep 4:4828. https://doi.org/10.1038/srep04828
Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504(7480):451–455. https://doi.org/10.1038/nature12726
Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K et al (2011) Enterotypes of the human gut microbiome. Nature 473(7346):174–180. https://doi.org/10.1038/nature09944
Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, Koga Y, Sudo N (2012) Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol 303(11):G1288–G1295. https://doi.org/10.1152/ajpgi.00341.2012
Azad MAK, Sarker M, Li T, Yin J (2018) Probiotic species in the modulation of gut microbiota: an overview. Biomed Res Int 2018:9478630. https://doi.org/10.1155/2018/9478630
Bayliss JA, Lemus M, Santos VV, Deo M, Elsworth JD, Andrews ZB (2016) Acylated but not des-acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson’s disease. J Neurochem 137(3):460–471. https://doi.org/10.1111/jnc.13576
Bekris LM, Mata IF, Zabetian CP (2010) The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 23(4):228–242. https://doi.org/10.1177/0891988710383572
Bercik P, Collins SM, Verdu EF (2012) Microbes and the gut-brain axis. Neurogastroenterol Motil 24(5):405–413. https://doi.org/10.1111/j.1365-2982.2012.01906.x
Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30(12):1600–1611. https://doi.org/10.1002/mds.26431
Bik EM, Ugalde JA, Cousins J, Goddard AD, Richman J, Apte ZS (2018) Microbial biotransformations in the human distal gut. Br J Pharmacol 175(24):4404–4414. https://doi.org/10.1111/bph.14085
Bourassa MW, Alim I, Bultman SJ, Ratan RR (2016) Butyrate, neuroepigenetics and the gut microbiome: can a high fiber diet improve brain health? Neurosci Lett 625:56–63. https://doi.org/10.1016/j.neulet.2016.02.009
Braak H, de Vos RA, Bohl J, Del Tredici K (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396(1):67–72. https://doi.org/10.1016/j.neulet.2005.11.012
Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, Casella G, Drew JC, Ilonen J, Knip M, Hyöty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz D, Atkinson MA, Triplett EW (2011) Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 6(10):e25792. https://doi.org/10.1371/journal.pone.0025792
Bullich C, Keshavarzian A, Garssen J, Kraneveld A, Perez-Pardo P (2019) Gut vibes in Parkinson’s disease: the microbiota-gut-brain axis. Mov Disord Clin Pract 6(8):639–651. https://doi.org/10.1002/mdc3.12840
Çamcı G, Oğuz S (2016) Association between Parkinson’s disease and Helicobacter pylori. J Clin Neurol 12(2):147–150. https://doi.org/10.3988/jcn.2016.12.2.147
Cao H, Liu X, An Y, Zhou G, Liu Y, Xu M, Dong W, Wang S, Yan F, Jiang K, Wang B (2017) Dysbiosis contributes to chronic constipation development via regulation of serotonin transporter in the intestine. Sci Rep 7(1):10322. https://doi.org/10.1038/s41598-017-10835-8
Carabotti M, Scirocco A, Maselli MA, Severi C (2015) The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 28(2):203–209
Cassani E, Privitera G, Pezzoli G, Pusani C, Madio C, Iorio L, Barichella M (2011) Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol Dietol 57(2):117–121
Cersósimo MG, Tumilasci OR, Raina GB, Benarroch EE, Cardoso EM, Micheli F, Pazo JH (2009) Hyposialorrhea as an early manifestation of Parkinson disease. Auton Neurosci 150(1–2):150–151. https://doi.org/10.1016/j.autneu.2009.04.004
Chen WC, Quigley EM (2014) Probiotics, prebiotics & synbiotics in small intestinal bacterial overgrowth: opening up a new therapeutic horizon! Indian J Med Res 140(5):582–584
Chen H, Zhao EJ, Zhang W, Lu Y, Liu R, Huang X, Ciesielski-Jones AJ, Justice MA, Cousins DS, Peddada S (2015) Meta-analyses on prevalence of selected Parkinson’s nonmotor symptoms before and after diagnosis. Transl Neurodegener 4(1):1. https://doi.org/10.1186/2047-9158-4-1
Chen T, Long W, Zhang C, Liu S, Zhao L, Hamaker BR (2017) Fiber-utilizing capacity varies in Prevotella-versus bacteroides-dominated gut microbiota. Sci Rep 7(1):2594. https://doi.org/10.1038/s41598-017-02995-4
Chen QQ, Haikal C, Li W, Li JY (2019) Gut inflammation in association with pathogenesis of Parkinson’s disease. Front Mol Neurosci 12:218. https://doi.org/10.3389/fnmol.2019.00218
Cirstea MS, Yu AC, Golz E, Sundvick K, Kliger D, Radisavljevic N, Foulger LH, Mackenzie M, Huan T, Finlay BB, Appel-Cresswell S (2020) Microbiota composition and metabolism are associated with gut function in Parkinson’s disease. Mov Disord 35(7):1208–1217. https://doi.org/10.1002/mds.28052
Costantini A, Pala MI, Grossi E, Mondonico S, Cardelli LE, Jenner C, Proietti S, Colangeli M, Fancellu R (2015) Long-term treatment with high-dose thiamine in Parkinson disease: an open-label pilot study. J Altern Complement Med 21(12):740–747. https://doi.org/10.1089/acm.2014.0353
Costea PI, Hildebrand F, Arumugam M, Bäckhed F, Blaser MJ, Bushman FD, de Vos WM, Ehrlich SD, Fraser CM, Hattori M, Huttenhower C, Jeffery IB, Knights D, Lewis JD, Ley RE, Ochman H, O’Toole PW, Quince C, Relman DA, Shanahan F et al (2018) Enterotypes in the landscape of gut microbial community composition. Nat Microbiol 3(1):8–16. https://doi.org/10.1038/s41564-017-0072-8
Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA (2012) The application of ecological theory toward an understanding of the human microbiome. Science 336(6086):1255–1262. https://doi.org/10.1126/science.1224203
Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13(10):701–712. https://doi.org/10.1038/nrn3346
Cryan JF, O’Mahony SM (2011) The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 23(3):187–192. https://doi.org/10.1111/j.1365-2982.2010.01664.x
D’Souza WN, Douangpanya J, Mu S, Jaeckel P, Zhang M, Maxwell JR, Rottman JB, Labitzke K, Willee A, Beckmann H, Wang Y, Li Y, Schwandner R, Johnston JA, Towne JE, Hsu H (2017) Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses. PLoS One 12(7):e0180190. https://doi.org/10.1371/journal.pone.0180190
Derrien M, Van Baarlen P, Hooiveld G, Norin E, Müller M, de Vos WM (2011) Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front Microbiol 2:166. https://doi.org/10.3389/fmicb.2011.00166
Derrien M, Belzer C, de Vos WM (2017) Akkermansia muciniphila and its role in regulating host functions. Microb Pathog 106:171–181. https://doi.org/10.1016/j.micpath.2016.02.005
Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S (2011) Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 108(7):3047–3052. https://doi.org/10.1073/pnas.1010529108
Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder MI, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H et al (2019) Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 5(1):eaau3333. https://doi.org/10.1126/sciadv.aau3333
Dutta SK, Verma S, Jain V, Surapaneni BK, Vinayek R, Phillips L, Nair PP (2019) Parkinson’s disease: the emerging role of gut dysbiosis, antibiotics, probiotics, and fecal microbiota transplantation. J Neurogastroenterol Motil 25(3):363–376. https://doi.org/10.5056/jnm19044
Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA (2005) Diversity of the human intestinal microbial flora. Science 308(5728):1635–1638. https://doi.org/10.1126/science.1110591
Escapa IF, Chen T, Huang Y, Gajare P, Dewhirst FE, Lemon KP (2018) New insights into human nostril microbiome from the expanded human oral microbiome database (eHOMD): a resource for the microbiome of the human aerodigestive tract. mSystems 3(6):e00187-18. https://doi.org/10.1128/mSystems.00187-18
Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF (2015) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 14(6):625–639. https://doi.org/10.1016/S1474-4422(15)00007-1
Fernández J, Redondo-Blanco S, Gutiérrez-del-Río I, Miguélez EM, Villar CJ, Lombó F (2016) Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: a review. J Funct Foods 25:511–522. https://doi.org/10.1016/j.jff.2016.06.032
Fleury V, Zekeridou A, Lazarevic V, Gaïa N, Giannopoulou C, Genton L, Cancela J, Girard M, Goldstein R, Bally JF, Mombelli A, Schrenzel J, Burkhard PR (2021) Oral dysbiosis and inflammation in Parkinson’s disease. J Parkinsons Dis 11(2):619–631. https://doi.org/10.3233/JPD-202459
Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A (2011) Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One 6(12):e28032. https://doi.org/10.1371/journal.pone.0028032
Foster KR, Schluter J, Coyte KZ, Rakoff-Nahoum S (2017) The evolution of the host microbiome as an ecosystem on a leash. Nature 548(7665):43–51. https://doi.org/10.1038/nature23292
Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM et al (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504(7480):446–450. https://doi.org/10.1038/nature12721
Galland L (2014) The gut microbiome and the brain. J Med Food 17(12):1261–1272. https://doi.org/10.1089/jmf.2014.7000
Galley JD, Nelson MC, Yu Z, Dowd SE, Walter J, Kumar PS, Lyte M, Bailey MT (2014) Exposure to a social stressor disrupts the community structure of the colonic mucosa-associated microbiota. BMC Microbiol 14:189. https://doi.org/10.1186/1471-2180-14-189
Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, Gasbarrini G (2007) Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 25(3):237–240. https://doi.org/10.1159/000103892
Gomez de Agüero M, Ganal-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H, Steinert A, Heikenwalder M, Hapfelmeier S, Sauer U, McCoy KD, Macpherson AJ (2016) The maternal microbiota drives early postnatal innate immune development. Science 351(6279):1296–1302. https://doi.org/10.1126/science.aad2571
Gray MT, Woulfe JM (2015) Striatal blood-brain barrier permeability in Parkinson’s disease. J Cereb Blood Flow Metab 35(5):747–750. https://doi.org/10.1038/jcbfm.2015.32
Grenham S, Clarke G, Cryan JF, Dinan TG (2011) Brain-gut-microbe communication in health and disease. Front Physiol 2:94. https://doi.org/10.3389/fphys.2011.00094
Guo Y, Nguyen KA, Potempa J (2010) Dichotomy of gingipains action as virulence factors: from cleaving substrates with the precision of a surgeon’s knife to a meat chopper-like brutal degradation of proteins. Periodontol 2000 54(1):15–44. https://doi.org/10.1111/j.1600-0757.2010.00377.x
Ha CW, Lam YY, Holmes AJ (2014) Mechanistic links between gut microbial community dynamics, microbial functions and metabolic health. World J Gastroenterol 20(44):16498–16517. https://doi.org/10.3748/wjg.v20.i44.16498
Håglin L, Johansson I, Forsgren L, Bäckman L (2017) Intake of vitamin B before onset of Parkinson’s disease and atypical parkinsonism and olfactory function at the time of diagnosis. Eur J Clin Nutr 71(1):97–102. https://doi.org/10.1038/ejcn.2016.181
Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K, Shibata A, Fujisawa Y, Minato T, Okamoto A, Ohno K, Hirayama M (2015) Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease. PLoS One 10(11):e0142164. https://doi.org/10.1371/journal.pone.0142164
Hawkes CH, Del Tredici K, Braak H (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33(6):599–614. https://doi.org/10.1111/j.1365-2990.2007.00874.x
Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B, Wilmes P (2018) The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord 33(1):88–98. https://doi.org/10.1002/mds.27105
Heinzel S, Aho VTE, Suenkel U, von Thaler AK, Schulte C, Deuschle C, Paulin L, Hantunen S, Brockmann K, Eschweiler GW, Maetzler W, Berg D, Auvinen P, Scheperjans F (2020) Gut microbiome signatures of risk and prodromal markers of Parkinson disease. Ann Neurol 88(2):320–331. https://doi.org/10.1002/ana.25788. (Retraction published Ann Neurol. 2021;90(2):329)
Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H (2017) Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov Disord 32(5):739–749. https://doi.org/10.1002/mds.26942
Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T (2016) The incidence of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology 46(4):292–300. https://doi.org/10.1159/000445751
Hoffman BU, Lumpkin EA (2018) A gut feeling. Science 361(6408):1203–1204. https://doi.org/10.1126/science.aau9973
Hooper LV, Littman DR, Macpherson AJ (2012) Interactions between the microbiota and the immune system. Science 336(6086):1268–1273. https://doi.org/10.1126/science.1223490
Houser MC, Chang J, Factor SA, Molho ES, Zabetian CP, Hill-Burns EM, Payami H, Hertzberg VS, Tansey MG (2018) Stool immune profiles evince gastrointestinal inflammation in Parkinson’s disease. Mov Disord 33(5):793–804. https://doi.org/10.1002/mds.27326
Hoyles L, Snelling T, Umlai UK, Nicholson JK, Carding SR, Glen RC, McArthur S (2018) Microbiome-host systems interactions: protective effects of propionate upon the blood-brain barrier. Microbiome 6(1):55. https://doi.org/10.1186/s40168-018-0439-y
Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow J, Reisman SE, Petrosino JF, Patterson PH, Mazmanian SK (2013) Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155(7):1451–1463. https://doi.org/10.1016/j.cell.2013.11.024
Hu LF, Wong PT, Moore PK, Bian JS (2007) Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. J Neurochem 100(4):1121–1128. https://doi.org/10.1111/j.1471-4159.2006.04283.x
Hu LF, Lu M, Tiong CX, Dawe GS, Hu G, Bian JS (2010) Neuroprotective effects of hydrogen sulfide on Parkinson’s disease rat models. Aging Cell 9(2):135–146. https://doi.org/10.1111/j.1474-9726.2009.00543.x
Jakobsson HE, Rodríguez-Piñeiro AM, Schütte A, Ermund A, Boysen P, Bemark M, Sommer F, Bäckhed F, Hansson GC, Johansson ME (2015) The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep 16(2):164–177. https://doi.org/10.15252/embr.201439263
Jhala SS, Hazell AS (2011) Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism. Neurochem Int 58(3):248–260. https://doi.org/10.1016/j.neuint.2010.11.019
Johnson KV, Foster KR (2018) Why does the microbiome affect behaviour? Nat Rev Microbiol 16(10):647–655. https://doi.org/10.1038/s41579-018-0014-3
Kaelberer MM, Buchanan KL, Klein ME, Barth BB, Montoya MM, Shen X, Bohórquez DV (2018) A gut-brain neural circuit for nutrient sensory transduction. Science 361(6408):eaat5236. https://doi.org/10.1126/science.aat5236
Kang Y, Kang X, Zhang H, Liu Q, Yang H, Fan W (2021) Gut microbiota and Parkinson’s disease: implications for faecal microbiota transplantation therapy. ASN Neuro 13:17590914211016217. https://doi.org/10.1177/17590914211016217
Kell DB, Pretorius E (2015) On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. Integr Biol 7(11):1339–1377. https://doi.org/10.1039/c5ib00158g
Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM (2015) Colonic bacterial composition in Parkinson’s disease. Mov Disord 30(10):1351–1360. https://doi.org/10.1002/mds.26307
Kida K, Yamada M, Tokuda K, Marutani E, Kakinohana M, Kaneki M, Ichinose F (2011) Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson’s disease. Antioxid Redox Signal 15(2):343–352. https://doi.org/10.1089/ars.2010.3671
Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F (2016) From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165(6):1332–1345. https://doi.org/10.1016/j.cell.2016.05.041
Latorre R, Sternini C, De Giorgio R, Greenwood-Van Meerveld B (2016) Enteroendocrine cells: a review of their role in brain-gut communication. Neurogastroenterol Motil 28(5):620–630. https://doi.org/10.1111/nmo.12754
LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M (2013) Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol 24(2):160–168. https://doi.org/10.1016/j.copbio.2012.08.005
Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14(5):501–503. https://doi.org/10.1038/nm1746
Li W, Wu X, Hu X, Wang T, Liang S, Duan Y, Jin F, Qin B (2017) Structural changes of gut microbiota in Parkinson’s disease and its correlation with clinical features. Sci China Life Sci 60(11):1223–1233. https://doi.org/10.1007/s11427-016-9001-4
Liepelt-Scarfone I, Gauss K, Maetzler W, Müller K, Bormann C, Fruhmann Berger M, Timmers M, Streffer J, Berg D (2013) Evaluation of progression markers in the premotor phase of Parkinson’s disease: the progression markers in the premotor phase study. Neuroepidemiology 41(3–4):174–182. https://doi.org/10.1159/000353560
Linden DR (2014) Hydrogen sulfide signaling in the gastrointestinal tract. Antioxid Redox Signal 20(5):818–830. https://doi.org/10.1089/ars.2013.5312
Liu X, Cao S, Zhang X (2015) Modulation of gut microbiota-brain axis by probiotics, prebiotics, and diet. J Agric Food Chem 63(36):7885–7895. https://doi.org/10.1021/acs.jafc.5b02404
Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, Shi J, Zhao S, Liu W, Wang X, Xia H, Liu Z, Cui B, Liang P, Xi L, Jin J, Ying X, Wang X, Zhao X, Li W et al (2017) Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 23(7):859–868. https://doi.org/10.1038/nm.4358
Liu J, Xu F, Nie Z, Shao L (2020) Gut microbiota approach—a new strategy to treat Parkinson’s disease. Front Cell Infect Microbiol 10:570658. https://doi.org/10.3389/fcimb.2020.570658
Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489(7415):220–230. https://doi.org/10.1038/nature11550
Lubomski M, Tan AH, Lim SY, Holmes AJ, Davis RL, Sue CM (2020) Parkinson’s disease and the gastrointestinal microbiome. J Neurol 267(9):2507–2523. https://doi.org/10.1007/s00415-019-09320-1
Maslowski KM, Mackay CR (2011) Diet, gut microbiota and immune responses. Nat Immunol 12(1):5–9. https://doi.org/10.1038/ni0111-5
McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 10(Suppl 1):S3–S7. https://doi.org/10.1016/j.parkreldis.2004.01.005
Mihaila D, Donegan J, Barns S, LaRocca D, Du Q, Zheng D, Vidal M, Neville C, Uhlig R, Middleton FA (2019) The oral microbiome of early stage Parkinson’s disease and its relationship with functional measures of motor and non-motor function. PLoS One 14(6):e0218252. https://doi.org/10.1371/journal.pone.0218252
Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K, Hirayama M (2017) Progression of Parkinson’s disease is associated with gut dysbiosis: two-year follow-up study. PLoS One 12(11):e0187307. https://doi.org/10.1371/journal.pone.0187307
Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, Kim S, Lee D, Chung H, Oh MS, Lee KT, Park S (2009) Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease by blocking microglial activation. Neurotox Res 15(4):332–347. https://doi.org/10.1007/s12640-009-9037-x
Morais LH, Schreiber HL IV, Mazmanian SK (2021) The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol 19(4):241–255. https://doi.org/10.1038/s41579-020-00460-0
Mulak A, Bonaz B (2015) Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol 21(37):10609–10620. https://doi.org/10.3748/wjg.v21.i37.10609
Müller T, Palluch R, Jackowski J (2011) Caries and periodontal disease in patients with Parkinson’s disease. Spec Care Dentist 31(5):178–181. https://doi.org/10.1111/j.1754-4505.2011.00205.x
Nakajima M, Arimatsu K, Kato T, Matsuda Y, Minagawa T, Takahashi N, Ohno H, Yamazaki K (2015) Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver. PLoS One 10(7):e0134234. https://doi.org/10.1371/journal.pone.0134234
Nishiwaki H, Ito M, Ishida T, Hamaguchi T, Maeda T, Kashihara K, Tsuboi Y, Ueyama J, Shimamura T, Mori H, Kurokawa K, Katsuno M, Hirayama M, Ohno K (2020) Meta-analysis of gut dysbiosis in Parkinson’s disease. Mov Disord 35(9):1626–1635. https://doi.org/10.1002/mds.28119
Noyce AJ, Silveira-Moriyama L, Gilpin P, Ling H, Howard R, Lees AJ (2012) Severe dysphagia as a presentation of Parkinson’s disease. Mov Disord 27(3):457–458. https://doi.org/10.1002/mds.24006
Olsen I (2015) From the Acta Prize Lecture 2014: the periodontal-systemic connection seen from a microbiological standpoint. Acta Odontol Scand 73(8):563–568. https://doi.org/10.3109/00016357.2015.1007480
Olsen I, Singhrao SK (2019) Is there a link between genetic defects in the complement cascade and Porphyromonas gingivalis in Alzheimer’s disease? J Oral Microbiol 12(1):1676486. https://doi.org/10.1080/20002297.2019.1676486
Olumuyiwa-Akeredolu OO, Page MJ, Soma P, Pretorius E (2019) Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis. Nat Rev Rheumatol 15(4):237–248. https://doi.org/10.1038/s41584-019-0187-9
Ostojic SM (2018) Inadequate production of H2 by gut microbiota and Parkinson disease. Trends Endocrinol Metab 29(5):286–288. https://doi.org/10.1016/j.tem.2018.02.006
Paiva I, Pinho R, Pavlou MA, Hennion M, Wales P, Schütz AL, Rajput A, Szego ÉM, Kerimoglu C, Gerhardt E, Rego AC, Fischer A, Bonn S, Outeiro TF (2017) Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage. Hum Mol Genet 26(12):2231–2246. https://doi.org/10.1093/hmg/ddx114
Parashar A, Udayabanu M (2017) Gut microbiota: implications in Parkinson’s disease. Parkinsonism Relat Disord 38:1–7. https://doi.org/10.1016/j.parkreldis.2017.02.002
Pereira PAB, Aho VTE, Paulin L, Pekkonen E, Auvinen P, Scheperjans F (2017) Oral and nasal microbiota in Parkinson’s disease. Parkinsonism Relat Disord 38:61–67. https://doi.org/10.1016/j.parkreldis.2017.02.026
Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaikh M, Voigt RM, Naqib A, Green SJ, Kordower JH, Shannon KM, Garssen J, Kraneveld AD, Keshavarzian A (2019) Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice. Gut 68(5):829–843. https://doi.org/10.1136/gutjnl-2018-316844
Peterson LJ, Flood PM (2012) Oxidative stress and microglial cells in Parkinson’s disease. Mediat Inflamm 2012:401264. https://doi.org/10.1155/2012/401264
Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, Florin TH (2010) Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 105(11):2420–2428. https://doi.org/10.1038/ajg.2010.281
Powell N, Walker MM, Talley NJ (2017) The mucosal immune system: master regulator of bidirectional gut-brain communications. Nat Rev Gastroenterol Hepatol 14(3):143–159. https://doi.org/10.1038/nrgastro.2016.191
Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, Chen SD, Xiao Q (2018) Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease. Brain Behav Immun 70:194–202. https://doi.org/10.1016/j.bbi.2018.02.016
Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73(11):1316–1324. https://doi.org/10.1001/jamaneurol.2016.2742
Queipo-Ortuño MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, Casanueva F, Tinahones FJ (2013) Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. PLoS One 8(5):e65465. https://doi.org/10.1371/journal.pone.0065465
Radaic A, Kapila YL (2021) The oralome and its dysbiosis: new insights into oral microbiome-host interactions. Comput Struct Biotechnol J 19:1335–1360. https://doi.org/10.1016/j.csbj.2021.02.010
Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y (2011) Helicobacter pylori eradication for Parkinson’s disease. Cochrane Database Syst Rev (11):CD008453. https://doi.org/10.1002/14651858.CD008453.pub2
Reichmann H (2011) View point: etiology in Parkinson’s disease. Dual hit or spreading intoxication. J Neurol Sci 310(1–2):9–11. https://doi.org/10.1016/j.jns.2011.04.016
Reid G, Younes JA, Van der Mei HC, Gloor GB, Knight R, Busscher HJ (2011) Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 9(1):27–38. https://doi.org/10.1038/nrmicro2473
Reunanen J, Kainulainen V, Huuskonen L, Ottman N, Belzer C, Huhtinen H, de Vos WM, Satokari R (2015) Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer. Appl Environ Microbiol 81(11):3655–3662. https://doi.org/10.1128/AEM.04050-14
Ruffmann C, Parkkinen L (2016) Gut feelings about α-synuclein in gastrointestinal biopsies: biomarker in the making? Mov Disord 31(2):193–202. https://doi.org/10.1002/mds.26480
Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167(6):1469–1480.e12. https://doi.org/10.1016/j.cell.2016.11.018
Santos SF, de Oliveira HL, Yamada ES, Neves BC, Pereira A Jr (2019) The gut and Parkinson’s disease—a bidirectional pathway. Front Neurol 10:574. https://doi.org/10.3389/fneur.2019.00574
Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P (2015) Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord 30(3):350–358. https://doi.org/10.1002/mds.26069
Schwab C, Berry D, Rauch I, Rennisch I, Ramesmayer J, Hainzl E, Heider S, Decker T, Kenner L, Müller M, Strobl B, Wagner M, Schleper C, Loy A, Urich T (2014) Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery. ISME J 8(5):1101–1114. https://doi.org/10.1038/ismej.2013.223
Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH (2013) The influence of diet on the gut microbiota. Pharmacol Res 69(1):52–60. https://doi.org/10.1016/j.phrs.2012.10.020
Sender R, Fuchs S, Milo R (2016a) Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164(3):337–340. https://doi.org/10.1016/j.cell.2016.01.013
Sender R, Fuchs S, Milo R (2016b) Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 14(8):e1002533. https://doi.org/10.1371/journal.pbio.1002533
Shanker J, Setty P, Arvind P, Nair J, Bhasker D, Balakrishna G, Kakkar VV (2013) Relationship between periodontal disease, Porphyromonas gingivalis, peripheral vascular resistance markers and coronary artery disease in Asian Indians. Thromb Res 132(1):e8–e14. https://doi.org/10.1016/j.thromres.2013.04.023
Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH (2012) Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Mov Disord 27(6):716–719. https://doi.org/10.1002/mds.25020
Singhrao SK, Harding A, Simmons T, Robinson S, Kesavalu L, Crean S (2014) Oral inflammation, tooth loss, risk factors, and association with progression of Alzheimer’s disease. J Alzheimers Dis 42(3):723–737. https://doi.org/10.3233/JAD-140387
Sommer F, Bäckhed F (2013) The gut microbiota—masters of host development and physiology. Nat Rev Microbiol 11(4):227–238. https://doi.org/10.1038/nrmicro2974
Song N, Wang W, Jia F, Du X, Xie A, He Q, Shen X, Zhang J, Rogers JT, Xie J, Jiang H (2017) Assessments of plasma ghrelin levels in the early stages of Parkinson’s disease. Mov Disord 32(10):1487–1491. https://doi.org/10.1002/mds.27095
Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF (2016) The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis? Neurochem Int 99:110–132. https://doi.org/10.1016/j.neuint.2016.06.011
Strandwitz P, Kim KH, Terekhova D, Liu JK, Sharma A, Levering J, McDonald D, Dietrich D, Ramadhar TR, Lekbua A, Mroue N, Liston C, Stewart EJ, Dubin MJ, Zengler K, Knight R, Gilbert JA, Clardy J, Lewis K (2019) GABA-modulating bacteria of the human gut microbiota. Nat Microbiol 4(3):396–403. https://doi.org/10.1038/s41564-018-0307-3
Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, Cui C, Shen YQ (2018) Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun 70:48–60. https://doi.org/10.1016/j.bbi.2018.02.005
Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, Ng SW, Ang SP, Chow SK, Tan CT, Yong HS, Marras C, Fox SH, Lim SY (2014) Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord 20(5):535–540. https://doi.org/10.1016/j.parkreldis.2014.02.019
Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, Ng SW, Ang SP, Chow SK, Loke MF, Vadivelu JS, Ibrahim N, Yong HS, Tan CT, Fox SH, Lang AE, Lim SY (2015) Helicobacter pylori infection is associated with worse severity of Parkinson’s disease. Parkinsonism Relat Disord 21(3):221–225. https://doi.org/10.1016/j.parkreldis.2014.12.009
Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, Faßbender K, Schwiertz A, Schäfer KH (2016) Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord 32:66–72. https://doi.org/10.1016/j.parkreldis.2016.08.019
Van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S (2019) Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat Commun 10(1):310. https://doi.org/10.1038/s41467-019-08294-y
Vogt SL, Peña-Díaz J, Finlay BB (2015) Chemical communication in the gut: effects of microbiota-generated metabolites on gastrointestinal bacterial pathogens. Anaerobe 34:106–115. https://doi.org/10.1016/j.anaerobe.2015.05.002
Voigt RM, Summa KC, Forsyth CB, Green SJ, Engen P, Naqib A, Vitaterna MH, Turek FW, Keshavarzian A (2016) The circadian clock mutation promotes intestinal dysbiosis. Alcohol Clin Exp Res 40(2):335–347. https://doi.org/10.1111/acer.12943
Vuuren MJV, Nell TA, Carr JA, Kell DB, Pretorius E (2020) Iron dysregulation and inflammagens related to oral and gut health are central to the development of Parkinson’s disease. Biomol Ther 11(1):30. https://doi.org/10.3390/biom11010030
Wallace CJK, Milev R (2017) The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry 16:14. https://doi.org/10.1186/s12991-017-0138-2
Wallen ZD, Appah M, Dean MN, Sesler CL, Factor SA, Molho E, Zabetian CP, Standaert DG, Payami H (2020) Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Dis 6:11. https://doi.org/10.1038/s41531-020-0112-6
Wang H, Liu X, Tan C, Zhou W, Jiang J, Peng W, Zhou X, Mo L, Chen L (2020) Bacterial, viral, and fungal infection-related risk of Parkinson’s disease: meta-analysis of cohort and case-control studies. Brain Behav 10(3):e01549. https://doi.org/10.1002/brb3.1549
Winter SE, Bäumler AJ (2014) Why related bacterial species bloom simultaneously in the gut: principles underlying the ‘Like will to like’ concept. Cell Microbiol 16(2):179–184. https://doi.org/10.1111/cmi.12245
Zhu F, Li C, Gong J, Zhu W, Gu L, Li N (2019) The risk of Parkinson’s disease in inflammatory bowel disease: a systematic review and meta-analysis. Dig Liver Dis 51(1):38–42. https://doi.org/10.1016/j.dld.2018.09.017
Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, Shi H, Robertson KD, Munn DH, Liu K (2012) Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol 302(12):G1405–G1415. https://doi.org/10.1152/ajpgi.00543.2011
Zuker CS (2015) Food for the brain. Cell 161(1):9–11. https://doi.org/10.1016/j.cell.2015.03.016
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Rajeev, A., Chattopadhyay, I. (2024). Role of Gut Brain and Gut Oral Axis in Progression of Parkinson’s Disease with Special Focus on Gut Microbes. In: Pathak, S., Banerjee, A. (eds) Gut Microbiome and Brain Ageing. Springer, Singapore. https://doi.org/10.1007/978-981-99-8803-7_13
Download citation
DOI: https://doi.org/10.1007/978-981-99-8803-7_13
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-8802-0
Online ISBN: 978-981-99-8803-7
eBook Packages: MedicineMedicine (R0)